|Articles|January 31, 2019

Eversana Reveals new Market Access Portfolio

Eversana, an independent provider of global services to the life sciences industry, annouced Health Strategies Insights by Eversana, a market access research and insights portfolio to help life sciences innovators make more informed decisions throughout the product lifecycle.

“The evolution of our market intelligence capabilities strengthens Eversana's growing life science platform,” said Rod Cavin, General Manager for Health Strategies Insights by Eversana. “The product portfolio provides valuable market access insights to leading global biopharmaceutical companies in various phases of product development across a number of therapeutic areas-helping our clients achieve commercial success.”

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related to this article

September 21st, 2026

Pharmaceutical Executive Daily: AbbVie Forms Ai-Powered Drug Discovery Partnership with Iambic

AbbVie partners with Iambic on AI-driven drug discovery as Telix Pharmaceuticals moves to acquire ITM Isotope Technologies in a multibillion-dollar radiopharmaceutical merger, Novo Nordisk's CagriSema outperforms Eli Lilly's tirzepatide in a head-to-head diabetes trial, and Jen Lamppa of Inovalon discusses how real-time clinical data is reshaping trial recruitment.

September 21st, 2026

Roundup: AbbVie & Iambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM

AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.

September 21st, 2026

CagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report

Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.

September 21st, 2026

How Clinical Data Layers Impact How Patient Availability is Determined

Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.

September 18th, 2026

Pharmaceutical Executive Daily: FDA Approves Fayuvi

FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.

September 18th, 2026

M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz

Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.

September 18th, 2026

FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A

FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.

Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.

September 18th, 2026

Why Executive MFN Deals Aren't Enough: Q&A with Joe Cunningham

Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.

Eversana Reveals new Market Access Portfolio

Related to this article

Trending on PharmExec

CagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report

Roundup: AbbVie & Iambic Enter Ai Drug Discovery Collaboration, Telix Merges with ITM

Understanding the Latest with MFN Pricing and What It Means to Pharma

The Battle to Own the GLP-1 Patient Journey

How Clinical Data Layers Impact How Patient Availability is Determined